ESKAPE 病原体中的抗微生物药物耐药性。
Antimicrobial Resistance in ESKAPE Pathogens.
机构信息
School of Chemistry and Molecular Biosciences, The University of Queensland, QLD, Australia.
Australian Infectious Diseases Research Centre, The University of Queensland, QLD, Australia.
出版信息
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
Abstract
Antimicrobial-resistant ESKAPE ( , , , , , and species) pathogens represent a global threat to human health. The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease, and increased death rates due to treatment failure and requires a coordinated global response for antimicrobial resistance surveillance. This looming health threat has restimulated interest in the development of new antimicrobial therapies, has demanded the need for better patient care, and has facilitated heightened governance over stewardship practices.
摘要
耐抗菌药物的 ESKAPE（肠杆菌科、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌和屎肠球菌）病原体对人类健康构成了全球性威胁。ESKAPE 病原体获得抗微生物耐药基因，减少了严重感染的治疗选择，增加了疾病负担，并因治疗失败而导致死亡率上升，需要采取协调一致的全球对策来进行抗微生物药物耐药性监测。这种迫在眉睫的健康威胁重新激发了人们对抗微生物治疗新疗法的开发兴趣，要求更好地护理患者，并促进加强对抗微生物药物管理实践的治理。
相似文献
1
Antimicrobial Resistance in ESKAPE Pathogens.
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
2
Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options.
Future Microbiol. 2020 May;15:649-677. doi: 10.2217/fmb-2019-0333. Epub 2020 Jun 4.
3
Clinical relevance of the ESKAPE pathogens.
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308. doi: 10.1586/eri.13.12.
4
Novel antimicrobial agents for combating antibiotic-resistant bacteria.
Adv Drug Deliv Rev. 2022 Aug;187:114378. doi: 10.1016/j.addr.2022.114378. Epub 2022 Jun 4.
5
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
Nat Rev Microbiol. 2024 Oct;22(10):598-616. doi: 10.1038/s41579-024-01054-w. Epub 2024 Jun 3.
6
Prevalence of Antibiotic Resistance of ESKAPE Pathogens Over Five Years in an Infectious Diseases Hospital from South-East of Romania.
Infect Drug Resist. 2021 Jun 24;14:2369-2378. doi: 10.2147/IDR.S312231. eCollection 2021.
7
ESKAPE in China: epidemiology and characteristics of antibiotic resistance.
Emerg Microbes Infect. 2024 Dec;13(1):2317915. doi: 10.1080/22221751.2024.2317915. Epub 2024 Feb 23.
8
A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01677-19.
9
ESKAPEing the labyrinth of antibacterial discovery.
Nat Rev Drug Discov. 2015 Aug;14(8):529-42. doi: 10.1038/nrd4572. Epub 2015 Jul 3.
10
Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
Int J Antimicrob Agents. 2024 May;63(5):107125. doi: 10.1016/j.ijantimicag.2024.107125. Epub 2024 Feb 29.
引用本文的文献
1
In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.
PLoS One. 2025 Sep 5;20(9):e0331440. doi: 10.1371/journal.pone.0331440. eCollection 2025.
2
A streamlined method to determine the antibiotic resistance of plaque-forming predatory bacteria.
Front Microbiol. 2025 Aug 19;16:1582371. doi: 10.3389/fmicb.2025.1582371. eCollection 2025.
3
Plastispheres as reservoirs of antimicrobial resistance: Insights from metagenomic analyses across aquatic environments.
PLoS One. 2025 Sep 3;20(9):e0330754. doi: 10.1371/journal.pone.0330754. eCollection 2025.
4
Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers.
Pharmaceuticals (Basel). 2025 Aug 13;18(8):1195. doi: 10.3390/ph18081195.
5
Optimization and Characterization of Bioactive Metabolites from Cave-Derived C1.
Biomolecules. 2025 Jul 24;15(8):1071. doi: 10.3390/biom15081071.
6
Determination of the prevalence of hypervirulent Klebsiella pneumoniae strains in Northeast Iran, Mashhad.
Sci Rep. 2025 Aug 27;15(1):31579. doi: 10.1038/s41598-025-16969-4.
7
Discovery of New Everninomicin Analogs from a Marine-Derived sp. by Metabolomics and Genomics Approaches.
Mar Drugs. 2025 Jul 31;23(8):316. doi: 10.3390/md23080316.
8
Synergistic action between peptide-neomycin conjugates and polymyxin B against multidrug-resistant gram-negative pathogens.
Front Microbiol. 2025 Aug 7;16:1605813. doi: 10.3389/fmicb.2025.1605813. eCollection 2025.
9
2‑Aminoimidazole-benzimidazole Conjugates Potentiate the Gram-Positive Selective Antibiotic Clarithromycin against .
ACS Med Chem Lett. 2025 Jul 1;16(8):1562-1568. doi: 10.1021/acsmedchemlett.5c00201. eCollection 2025 Aug 14.
10
Antibacterial activity and mechanism of naphthoquine phosphate against ceftazidime-resistant via cell membrane disruption and ROS induction.
Front Microbiol. 2025 Aug 4;16:1603462. doi: 10.3389/fmicb.2025.1603462. eCollection 2025.
本文引用的文献
1
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel 4-Antigen Vaccine (SA4Ag).
Open Forum Infect Dis. 2019 Dec 24;7(1):ofz532. doi: 10.1093/ofid/ofz532. eCollection 2020 Jan.
2
Low prevalence of livestock-associated methicillin-resistant Staphylococcus aureus clonal complex 398 and mecC MRSA among human isolates in North-West England.
J Appl Microbiol. 2020 Jun;128(6):1785-1792. doi: 10.1111/jam.14578. Epub 2020 Jan 24.
3
Effect of tolerance on the evolution of antibiotic resistance under drug combinations.
Science. 2020 Jan 10;367(6474):200-204. doi: 10.1126/science.aay3041.
4
The global preclinical antibacterial pipeline.
Nat Rev Microbiol. 2020 May;18(5):275-285. doi: 10.1038/s41579-019-0288-0. Epub 2019 Nov 19.
5
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S519-S520. doi: 10.1093/cid/ciz823.
6
The Global Ascendency of OXA-48-Type Carbapenemases.
Clin Microbiol Rev. 2019 Nov 13;33(1). doi: 10.1128/CMR.00102-19. Print 2019 Dec 18.
7
Becomes Susceptible to Polymyxin B and Colistin in the Presence of PBT2.
ACS Infect Dis. 2020 Jan 10;6(1):50-55. doi: 10.1021/acsinfecdis.9b00307. Epub 2019 Nov 11.
8
The role of new β-lactamase inhibitors in gram-negative infections.
Curr Opin Infect Dis. 2019 Dec;32(6):638-646. doi: 10.1097/QCO.0000000000000600.
9
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
JAMA. 2019 Nov 5;322(17):1661-1671. doi: 10.1001/jama.2019.15468.
10
Ceftobiprole: drug evaluation and place in therapy.
Expert Rev Anti Infect Ther. 2019 Sep;17(9):689-698. doi: 10.1080/14787210.2019.1667229. Epub 2019 Sep 25.
Zotero 插件